ATTR-CM Diagnosis Lags by More Than a Year After HF in Medicare Population

Why It Matters

Prolonged diagnostic delays limit access to disease‑modifying therapies, worsening outcomes and increasing health‑system costs. Recognizing the lag can drive earlier testing and improve care pathways for a growing, high‑risk population.

Key Takeaways

• Median 494 days from heart failure to ATTR‑CM diagnosis in Medicare patients
• 64% of patients waited ≥6 months for ATTR‑CM confirmation
• Women and comorbidities increase odds of delayed ATTR‑CM diagnosis
• Diagnostic anchoring to common HF causes prolongs amyloidosis detection
• No improvement in diagnostic timeline 2016‑2022 despite rising case counts

Pulse Analysis

Transthyretin cardiac amyloidosis, once deemed rare, is now recognized as an emerging cause of heart failure in older adults. The disease’s infiltrative nature mimics more common cardiomyopathies, leading clinicians to attribute symptoms to familiar conditions such as aortic stenosis or coronary artery disease. As a result, many patients remain undiagnosed until advanced stages, missing the window for novel TTR‑targeted agents that can halt disease progression and improve survival. Understanding the epidemiology of ATTR‑CM is essential for payers and providers seeking to allocate resources efficiently in an aging Medicare population.

The recent JAMA Cardiology analysis of nearly 8,000 Medicare enrollees quantifies this problem: a median lag of 494 days from first heart‑failure diagnosis to confirmed ATTR‑CM, stretching to 840 days when early diuretic use marks symptom onset. Over half of the cohort experienced delays of six months or more, with women disproportionately affected despite representing only 23% of cases. Comorbidities that independently cause HF—such as COPD, hypertension, and diabetes—further obscure the amyloid signal, a classic case of diagnostic anchoring that inflates time to appropriate therapy. These data reveal that even as overall case identification rises, the diagnostic pathway has stagnated.

For health systems, the implication is clear: integrating routine amyloid screening—using non‑invasive scintigraphy or plasma TTR assays—into HF work‑ups for high‑risk groups could truncate the diagnostic odyssey. Policy makers might consider incentivizing early testing through bundled payments or quality metrics tied to timely ATTR‑CM identification. Meanwhile, ongoing research into artificial‑intelligence‑driven risk models promises to flag patients whose symptom patterns deviate from typical HF trajectories, offering a pragmatic route to earlier intervention and better outcomes.